ArticleNature medicine2023

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.

Jason J Luke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.